While we have relatively limited information regarding the prevalence of obsessive-compulsive disorder (OC) during pregnancy and the postpartum period. Previous studies have indicated that women may be more vulnerable to the onset of OCD during the postpartum period. Other studies indicate that women with OCD may experience worsening of OCD [...]
Postpartum depression (PPD) is a relatively common problem, affecting between 10% and 15% of women after delivery. Although it is difficult to reliably predict which women in the general population will experience postpartum depression, it is possible to identify certain subgroups of women who are at increased risk for postpartum [...]
This international survey demonstrates that pregnant and postpartum women are more likely to report elevated symptoms of depression, anxiety, and post-traumatic stress than others in the general population in the context of the COVID-19 pandemic.
In childhood, ADHD is clearly more common in boys than in girls; however, in adult samples, the sex differences in prevalence are mush smaller. There is also increasing recognition that girls and women may present with a different constellation of symptoms and behaviors. For example, in children, girls are more [...]
Many women ask about the safety of drinking caffeinated beverages during pregnancy.
A recent study looked at this question, analyzing data from the NICHD Fetal Growth Studies–Singletons, which included a group of 2,055 nonsmoking women at low risk for fetal growth problems. Caffeine consumption was evaluated using plasma concentrations of caffeine and paraxanthine (a metabolite of caffeine) and self-reported caffeinated beverage consumption at 10 to 13 weeks gestation.
Bupropion is commonly used to treat depression, and is also prescribed to support smoking cessation. Early data on bupropion-exposure during pregnancy raised concern for a possible increase in risk of malformations of the heart and large blood vessels in bupropion-exposed infants. Subsequent data from bupropion pregnancy registries has been reassuring, however, and do not demonstrate an overall increase in risk of cardiac defects following first trimester bupropion exposure. Although the overall risk of cardiac defects was not increased, the distribution of specific defects in these registries was unexpected in some ways. For example, the GlaxoSmithKline Bupropion Pregnancy Registry included two cases of coarctation of the aorta out of the 675 bupropion-exposed infants, compared to the rate of 6 cases per 10,000 births in the general population.